big pharma hasn’t taken a bite yet so there must be some decent risks in ph3 result - dropping $500M is nothing for big pharma vs potential sales of few $B per year
Ann: Opthea Completes Enrollment in Phase 3 Clinical Program, page-19
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
-0.005(0.76%) |
Mkt cap ! $800.2M | |||
| Open | High | Low | Value | Volume |
| 64.0¢ | 65.5¢ | 63.5¢ | $1.977M | 3.065M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13502 | 64.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.5¢ | 15085 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |